Arsanis (NASDAQ:ASNS) vs. Heska (HSKA) Head-To-Head Analysis

Heska (NASDAQ:HSKA) and Arsanis (NASDAQ:ASNS) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, earnings, risk, profitability, valuation and dividends.


This table compares Heska and Arsanis’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Heska 4.67% 11.49% 8.75%
Arsanis N/A N/A N/A

Institutional and Insider Ownership

89.2% of Heska shares are held by institutional investors. Comparatively, 68.7% of Arsanis shares are held by institutional investors. 15.9% of Heska shares are held by insiders. Comparatively, 50.9% of Arsanis shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Analyst Ratings

This is a summary of recent recommendations and price targets for Heska and Arsanis, as provided by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Heska 0 1 5 0 2.83
Arsanis 0 3 1 0 2.25

Heska presently has a consensus target price of $107.50, suggesting a potential upside of 7.34%. Arsanis has a consensus target price of $18.50, suggesting a potential upside of 905.43%. Given Arsanis’ higher possible upside, analysts plainly believe Arsanis is more favorable than Heska.

Valuation and Earnings

This table compares Heska and Arsanis’ gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Heska $129.34 million 5.81 $9.95 million $2.07 48.38
Arsanis N/A N/A -$33.87 million ($16.23) -0.11

Heska has higher revenue and earnings than Arsanis. Arsanis is trading at a lower price-to-earnings ratio than Heska, indicating that it is currently the more affordable of the two stocks.


Heska beats Arsanis on 10 of the 12 factors compared between the two stocks.

Heska Company Profile

Heska Corporation manufactures, sells, and markets veterinary diagnostic and specialty products for canine and feline healthcare markets in the United States, Canada, Europe, and internationally. The company's Core Companion Animal Health segment offers Element DC and DRI-CHEM 7000 veterinary chemistry analyzers for blood chemistry and electrolyte analysis; HT5 and HEMATRUE veterinary hematology analyzers to measure blood cell and platelet count, and hemoglobin levels; Element POC blood gas and electrolyte analyzers; COAG veterinary analyzers; Element i immunodiagnostic analyzers; and IV infusion pumps. This segment also provides veterinary imaging instruments and services, such as digital radiography solutions and ultrasound systems, as well as sells mobile digital radiography products; Cloudbank, a Web-based image storage solution; ViewCloud, a picture archival and communications system for Cloudbank; point-of-care heartworm diagnostic test products for dogs and cats; TRI-HEART Plus chewable tablets for the treatment of canine heartworm infection, and treatment and control of ascarid and hookworm infections; and allergy products and services, including ALLERCEPT definitive allergen panels, and therapy shots or drops. Its Other Vaccines, Pharmaceuticals and Products segment offers bovine vaccines primarily under the Titanium and MasterGuard brands; biological and pharmaceutical products for other animal health companies; and turnkey services comprising research, licensing, production, labeling, and packaging. The company sells its products to veterinarians through a field organization and third-party distributors; and trade shows, print advertising, and other distribution relationships. Heska Corporation has product development partnership and licensing agreement with MBio Diagnostics, Inc. The company was formerly known as Paravax, Inc. and changed its name to Heska Corporation. Heska Corporation was founded in 1988 and is headquartered in Loveland, Colorado.

Arsanis Company Profile

Arsanis, Inc., a clinical-stage biopharmaceutical company, focuses on applying monoclonal antibody (mAb) immunotherapies to address infectious diseases. Its lead product candidate is ASN100, a mAb therapeutic in Phase II clinical development for the prevention of staphylococcus aureus pneumonia in mechanically ventilated patients. The company's preclinical pipeline comprises mAbs targeting various bacterial and viral pathogens, including respiratory syncytial virus. Arsanis, Inc. was founded in 2010 and is headquartered in Waltham, Massachusetts.

Receive News & Ratings for Heska Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heska and related companies with's FREE daily email newsletter.

Leave a Reply